| 货号 | 9410-AN-050 |
| 别名 | 35-alpha calcimedin; Annexin A3; annexin A3,1,2-cyclic-inositol-phosphate phosphodiesterase; Annexin III; Annexin-3; ANXA3; Calcimedin 35-alpha ; calcimedin 35-alpha; Lipocortin III; PAP-III; Placental anticoagulant protein III; placental anticoagulant protein III, calcimedin 35-alpha |
| 来源 | E. coli-derived Ala2-Asp323, with a C-terminal 6-His tag |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 306 (Human); 11745 (Mouse); 25291 (Rat) |
| 内毒素水平 | <0.10 EU per 1 μg of the protein by the LAL method. |
| 生物活性 | Bioassay data are not available. |
| 溶解方法 | Reconstitute at 250 μg/mL in PBS. |
| 背景 | Annexin A3 (ANXA3), also known as Annexin III and Lipocortin III (LPC3),is a 37 kDa member of the Annexin family. Annexinsare calcium-dependent phospholipid-binding proteins that are preferentiallylocated on the cytosolic face of the plasma membrane. The Annexins consist of aunique N-terminal domain followed by a homologous C-terminal core domaincontaining the phospholipid-binding sites. The C-terminal domain is comprisedof four 60‑70 aa annexin repeats which form a tightly packed disc known as theannexin domain. Members of the Annexin family play a role in cytoskeletalinteractions, phospholipase inhibition, regulation of cellular growth, andintracellular signal transduction pathways (1). Annexin A3 is up-regulated in microglia following stroke and in parenchymal hepatocytesin regenerating liver (2, 3). It can be up- or down‑regulated in variouscarcinomas (4). Alternate splicing generates an additional isoform with a 30amino acid (aa) deletion near the N-terminus (5). Human Annexin A3 shares 89% and 85% aa sequence identity with mouse and rat Annexin A3, respectively. |
| Accession # | P12429 N-terminal Se |
| 运输条件 | Blue Ice |
| 预期分子量 | 37 kDa |
| SDS-PAGE | 36 kDa, reducing conditions |
| 存放说明 | -20℃ |
| 纯度 | >95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| 参考文献 |
|
R&D Systems proteins are almost always sold with a bioassay to indicate activity. However, we recognize that sometimes proteins might be novel, and their bioactivity may not be well understood. In addition, some researchers may wish to use polypeptides to make antibodies. To facilitate the advancement of new science, we now offer our Innovator Series of proteins. |
